DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group R — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group R maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group r is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAD51 recombinase (RAD51) — RAD51 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9TRM · 2.4 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
Fanconi anemia complementation group R is not mentioned in any of the three abstracts provided. The 2012 review covers clinical features, diagnostic criteria, and therapies for Fanconi anemia generally, but gives no specific numbers for survival, response rates, or sample sizes. The 2001 study identifies a cytoplasmic serine protein kinase (FANCA-PK) that binds and phosphorylates FANCA in a complex, is sensitive to wortmannin, and is defective in patient-derived lymphoblasts, but the kinase itself is not named and no patient outcomes are reported. The 2016 review argues that TGF-β is a master regulator of bone marrow failure in Fanconi anemia, but again provides no quantitative data from trials or cohorts.
No drug is tested or repurposed in any of these abstracts. The 2001 paper mentions wortmannin only as a laboratory tool to characterise the kinase, not as a therapeutic. There is no evidence for any intervention in Fanconi anemia complementation group R specifically, and no clinical results of any kind.
What is missing: any clinical trial testing a drug in Fanconi anemia complementation group R; any patient-derived data for this subgroup; any identified drug candidate; any funding for a trial targeting this complementation group; any method to stratify patients by complementation group R in a clinical setting.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Investigation · 2012 · 287 citations · open access
Molecular pathogenesis and clinical management of Fanconi anemia
AbstractFanconi anemia (FA) is a rare genetic disorder associated with a high frequency of hematological abnormalities and congenital anomalies. Based on multilateral efforts from basic scientists and clinicians, significant advances in our knowledge of FA have been made in recent years. Here we review the clinical features, the diagnostic criteria, and the current and future therapies of FA and describe the current understanding of the molecular basis of the disease.
A cytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA
AbstractFanconi anemia (FA) is an autosomal recessive disease with congenital anomalies, bone marrow failure, and susceptibility to leukemia. Patient cells show chromosome instability and hypersensitivity to DNA cross-linking agents. At least 8 complementation groups (A-G) have been identified and 6 FA genes (for subtypes A, C, D2, E, F, and G) have been cloned. Increasing evidence indicates that a protein complex assembly of multiple FA proteins, including FANCA and FANCG, plays a crucial role in the FA pathway. Previously, it was reported that FANCA was phosphorylated in lymphoblasts from normal controls, whereas the phosphorylation was defective in those derived from patients with FA of multiple complementation groups. The present study examined phosphorylation of FANCA ectopically expressed in FANCA(-) cells. Several patient-derived mutations abrogated in vivo phosphorylation of FANCA in this system, suggesting that FANCA phosphorylation is associated with its function. In vitro phosphorylation studies indicated that a physiologic protein kinase for FANCA (FANCA-PK) forms a complex with the substrate. Furthermore, at least a part of FANCA-PK as well as phosphorylated FANCA were included in the FANCA/FANCG complex. Thus, FANCA-PK appears to be another component of the FA protein complex and may regulate function of FANCA. FANCA-PK was characterized as a cytoplasmic serine kinase sensitive to wortmannin. Identification of the protein kinase is expected to elucidate regulatory mechanisms that control the FA pathway.
South African Medical Journal · 2018 · 9 citations · open access
Fanconi anaemia in South Africa: Past, present and future
AbstractFanconi anaemia (FA) is an inherited genetic disorder characterised by somatic anomalies, bone marrow failure and an increased predisposition to solid tumours and haematological malignancies. South African (SA) black and Afrikaner individuals are at higher than average risk for this condition owing to genetic founder mutations in certain Fanconi-associated genes. This review explores the epidemiology, clinical presentation, diagnostic modalities and recommended care of affected patients, focusing on the founder population groups in SA. The early diagnosis of FA is important and provides improved opportunities for early intervention, but remains challenging.
TGF-β: a master regulator of the bone marrow failure puzzle in Fanconi anemia
AbstractFanconi anemia (FA) is a genetic disease mainly characterized by progressive bone marrow failure (BMF), congenital abnormalities, and increased predisposition to cancer (1,2). Although most patients with FA develop BMF generally during childhood, the molecular mechanism underlying BMF has remained elusive for a long time and is still a matter of debate.
National Journal of Health Sciences · 2019 · 1 citations · open access
Fanconi Anemia
AbstractFanconi anemia(FA) is the most common inherited bone marrow failure disorder characterized by cytopenias, somatic defects and increased propensity to develop malignancies. Chromosomal breakage analysis is the gold standard diagnostic test for this disease but it may produce false negative results. Therefore, genetic analysis is necessary for confirmation and complement group identification that will help in prenatal diagnosis. Phenotypic presentation of FA is quite variable. 20-30% patients are physically normal. Affected patients may exhibit anamolies of multiple organs or just a few caf au lait spots. Therefore diagnosis of this disease remains challenging. Similar to its phenotype the pathophysiology of this disease is also complicated and still not completely understood. The basic defect is in the DNA repair mechanism. The 21 complementation genes responsible for DNA repair are hampered at any one or multiple levels. The chromosomes from the cells of these patients therefore show spontaneous breakages. The incidence of this disease throughout the world is very rare about 1-2/350000 persons. It is more common in Jews. In Pakistan incidence of FA is still not known and many of the physicians and surgeons don't have in depth knowledge as they consider it as a rare disease. However, because of the custom of inter marriages its incidence may be surprisingly high. Therefore in depth knowledge of this disease is necessary.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
